Sangamo Therapeutics, Inc.

SGMO

HealthcareBiotechnologyNASDAQ

$0.14

Market Cap: $58.41M

Sangamo Therapeutics, Inc. (SGMO) Valuation Summary

Updated Apr 6, 2026 22:28

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$0.09 – $4.15	$0.51	+84.3%
Revenue DCF 10Y	—	N/A	—
▸ Trading Multiples
EV/Revenue	$1.81 – $21.54	$3.96	+1320.2%

Valuation History

DCF Analysis

Sangamo Therapeutics, Inc. (SGMO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.51

Market Price

$0.14

Upside / Downside

+261.7%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -179.9% to a target of 13.3% over 5 years, discounted at a WACC of 8.3%, Sangamo Therapeutics, Inc. (SGMO) has an intrinsic value of $0.51 per share (range: $0.09 – $4.15).

Key Assumptions

Current Operating Margin

-179.9%

Target Operating Margin

13.3%

WACC

8.3%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

12.8%

Target CapEx/Rev

22.4%

D&A/Revenue

14.9%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2025	65	13.3%	-141.2%	-92	-92	10	(10)	4	-97	-93
2026	55	-15.4%	-102.6%	-57	-57	8	(9)	1	-59	-52
2027	146	164.2%	-64.0%	-94	-94	22	(27)	-9	-90	-74
2028	270	84.3%	-25.3%	-68	-68	40	(55)	-12	-71	-54
2029	402	49.0%	13.3%	54	42	60	(90)	-13	26	18

Enterprise Value Bridge

Sum of PV(FCFF)-255

Terminal Value (Gordon Growth at 3.0%)496

PV of Terminal Value347

Enterprise Value92

(–) Net Debt-11

Equity Value104

(÷) Shares Outstanding202

Fair Value per Share$0.51

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.3%	$-1	$1	$2	$3	$4
7.3%	$-1	$0	$1	$2	$3
8.3%	$-1	$-0	$1	$1	$2
9.3%	$-1	$-0	$0	$1	$1
10.3%	$-1	$-1	$-0	$0	$1

Current price: $0.14. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at -9.9% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$2.13

Market Price

$0.14

Upside / Downside

+1407.3%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Sangamo Therapeutics, Inc. (SGMO) has a fair value of $2.13 based on 7 comparable companies in the Biotechnology industry.

EV/Revenue Valuation — Biotechnology

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Sangamo Therapeutics, Inc.SGMO	40	1.1x	0.7x
Armata Pharmaceuticals, Inc.ARMP	386	135.8x	131.1x
C4 Therapeutics, Inc.CCCC	235	6.1x	10.2x
OmniAb, Inc.OABI	175	9.1x	6.1x
Codexis, Inc.CDXS	172	2.8x	2.6x
Milestone Pharmaceuticals Inc.MIST	131	75.0x	2.2x
Insight Molecular Diagnostics Inc.IMDX	90	20.3x	58.0x
Rani Therapeutics Holdings, Inc.RANI	54	24.4x	4.4x
Industry Median		20.3x	6.1x
(*) Revenue		40	65
= Enterprise Value		803	399
(-) Net Debt		6	6
Equity Value		798	393
(/) Outstanding shares		280	280
Fair Price		$3	$1

Selected Fair Value (avg of trailing + forward)

$2.13

+1407.3%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$0.09 – $4.15

$0.51

+84.3%

Revenue DCF 10Y

—

N/A

—

▸ Trading Multiples

EV/Revenue

$1.81 – $21.54

$3.96

+1320.2%

DCF Analysis

Sangamo Therapeutics, Inc. (SGMO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.51

Market Price

$0.14

Upside / Downside

+261.7%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-179.9%

Target Operating Margin

13.3%

WACC

8.3%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

12.8%

Target CapEx/Rev

22.4%

D&A/Revenue

14.9%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2025	65	13.3%	-141.2%	-92	-92	10	(10)	4	-97	-93
2026	55	-15.4%	-102.6%	-57	-57	8	(9)	1	-59	-52
2027	146	164.2%	-64.0%	-94	-94	22	(27)	-9	-90	-74
2028	270	84.3%	-25.3%	-68	-68	40	(55)	-12	-71	-54
2029	402	49.0%	13.3%	54	42	60	(90)	-13	26	18

Enterprise Value Bridge

Sum of PV(FCFF)-255

Terminal Value (Gordon Growth at 3.0%)496

PV of Terminal Value347

Enterprise Value92

(–) Net Debt-11

Equity Value104

(÷) Shares Outstanding202

Fair Value per Share$0.51

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.3%	$-1	$1	$2	$3	$4
7.3%	$-1	$0	$1	$2	$3
8.3%	$-1	$-0	$1	$1	$2
9.3%	$-1	$-0	$0	$1	$1
10.3%	$-1	$-1	$-0	$0	$1

Current price: $0.14. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at -9.9% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$2.13

Market Price

$0.14

Upside / Downside

+1407.3%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Sangamo Therapeutics, Inc. (SGMO) has a fair value of $2.13 based on 7 comparable companies in the Biotechnology industry.

EV/Revenue Valuation — Biotechnology

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Sangamo Therapeutics, Inc.SGMO	40	1.1x	0.7x
Armata Pharmaceuticals, Inc.ARMP	386	135.8x	131.1x
C4 Therapeutics, Inc.CCCC	235	6.1x	10.2x
OmniAb, Inc.OABI	175	9.1x	6.1x
Codexis, Inc.CDXS	172	2.8x	2.6x
Milestone Pharmaceuticals Inc.MIST	131	75.0x	2.2x
Insight Molecular Diagnostics Inc.IMDX	90	20.3x	58.0x
Rani Therapeutics Holdings, Inc.RANI	54	24.4x	4.4x
Industry Median		20.3x	6.1x
(*) Revenue		40	65
= Enterprise Value		803	399
(-) Net Debt		6	6
Equity Value		798	393
(/) Outstanding shares		280	280
Fair Price		$3	$1

Selected Fair Value (avg of trailing + forward)

$2.13

+1407.3%